Luye Pharma’s Weekly Rivastigmine Patch Approved in Japan for Alzheimer’s
China-based Luye Pharma Group (HKG: 2186) announced that it has received marketing approval from Japan’s...
HKG: 2186
Luye Pharma Group Reports 2024 Revenue Dip Despite Growth in Product Sales
China-based Luye Pharma Group (HKG: 2186) announced its 2024 financial performance, recording RMB 6.061 billion...
Luye Pharma’s Shandong Boan Bio Reports 17.5% Revenue Growth in 2024
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...
Luye Pharma’s BA1302 Receives FDA Orphan Drug Designation for Lung and Pancreatic Cancer
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...
Luye Pharma Launches Erzofri in US Market
China-based Luye Pharma Group (HKG: 2186) has announced the initiation of commercialization of its in-house...
Luye Pharma’s Zepzelca Receives NMPA Approval for Metastatic Small Cell Lung Cancer Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from...
Luye Pharma’s Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955),...
Luye Pharma’s Subsidiary Boan Biotech Partners with Haier Biomedical for Pharmaceutical Industry Digitalization
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...
Luye Pharma Group’s 2024H1 Revenue and Net Profits Surge, Driven by Oncology and CNS Therapy Revenues
Luye Pharma Group, a China-based pharmaceutical company listed in Hong Kong (HKG: 2186), has reported...
Luye Pharma’s Subsidiary Boan Bio Reports 2024H1 Revenue Growth and First Full Year of Profitability
Luye Pharma Group, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2186), has announced...
Luye Pharma’s LY03020 Receives NMPA Approval for Schizophrenia and Alzheimer’s Psychosis Treatment
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that it has received...
Luye Pharma’s Antipsychotic Erzofri Gains FDA Nod for Schizophrenia Treatment
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has achieved a...
Luye Pharma’s Subsidiary Gets NMPA Go-Ahead for First CD228-Targeted ADC BA1302
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a subsidiary of China-based Luye Pharma Group (HKG:...
Luye Pharma Group Secures RMB 1.6 Billion Investment to Boost Financials and R&D
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
Luye Pharma’s Oxycodone/Naloxone Product Receives NMPA Approval for Severe Pain Management
Luye Pharma Group (HKG: 2186), a pharmaceutical company based in China, has announced that it...
Luye Pharma’s Manufacturing Facility Passes FDA Inspection for Paliperidone Palmitate Product
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that it has successfully...
Luye Pharma’s Once-Weekly Parkinson’s Disease Treatment Receives NMPA Approval
Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from the...
Luye Pharma’s Paliperidone Palmitate Injection Wins NMPA Nod for Schizophrenia Treatment
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
Luye Pharma Submits Market Approval Application for Rivastigmine Patch in Japan
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...
Luye Pharma’s Subsidiary Gets NMPA Green Light for Biosimilar Xgeva
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a controlling subsidiary of China-based Luye Pharma Group...